Finance Watch: Vicebio Adds To 2024’s Mega-Round Total With $100m Series B
J&J Innovation-Backed ONL Raised $65m Series D
Executive Summary
Private Company Edition: Vicebio plans to take a combo vaccine into Phase I with its $100m series B venture capital round. Also, Nura Bio raised $68m to boost its series A total to $141m and George Church-founded GC Therapeutics launched with $75m, among other recent VC deals.